Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, due to alleged misleading statements regarding the company's manufacturing and regulatory prospects [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Inovio made false statements about the manufacturing quality of its CELLECTRA device and the likelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 [5]. - The lawsuit alleges that Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [5]. - Investors are encouraged to join the class action without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by April 7, 2026, to represent the interests of other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A class action lawsuit has been initiated against Inovio Pharmaceuticals, Inc. for allegedly misleading investors regarding the manufacturing and regulatory prospects of its INO-3107 Biologics License Application [1][3]. Group 1: Lawsuit Details - The class action is on behalf of investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, with a deadline to file a lead plaintiff motion by April 7, 2026 [1]. - The lawsuit claims that Inovio made false and misleading statements about the manufacturing quality of its CELLECTRA device and the likelihood of submitting the INO-3107 BLA to the FDA by the second half of 2024 [3]. - It is alleged that Inovio lacked sufficient information to support the eligibility of INO-3107 for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [3]. Group 2: Regulatory Developments - On December 29, 2025, the FDA accepted Inovio's BLA for INO-3107 for standard review but noted that the company did not provide adequate information for accelerated approval [4]. - Inovio announced it does not plan to pursue approval under the standard review timeline and intends to meet with the FDA to discuss options for accelerated approval [4]. Group 3: Market Reaction - Following the FDA's announcement, Inovio's stock price dropped by $0.56, or 24.45%, closing at $1.73 per share on December 29, 2025 [5].

Core Viewpoint - INOVIO is actively participating in several upcoming scientific and investor conferences to showcase its advancements in DNA medicines aimed at treating HPV-associated diseases, cancer, and infectious diseases [1] Conference Participation - INOVIO will present at the American Association for Cancer Research Immuno-Oncology Conference on February 18, focusing on the treatment of Recurrent Respiratory Papillomatosis (RRP) with DNA immunotherapy INO-3107 [1] - The company will also participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, featuring a fireside chat webcast [1] - At the Festival of Biologics on March 4, INOVIO will present findings on the safety and pharmacokinetics of SARS-CoV-2 DNA-Encoded Monoclonal Antibodies in a Phase 1 trial [1] - The Citizens Life Sciences Conference on March 10 will include another fireside chat with INOVIO's management team [1] Company Overview - INOVIO is a biotechnology company dedicated to developing and commercializing DNA medicines that empower the body to produce its own disease-fighting tools [1]

LOS ANGELES--(BUSINESS WIRE)--Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – INO. ...

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. for alleged misleading statements and failure to disclose critical information regarding its CELLECTRA device and the INO-3107 Biologics License Application [2][6]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Inovio securities between October 10, 2023, and December 26, 2025, with a deadline of April 7, 2026, for investors to apply as lead plaintiffs [2]. - Allegations include deficiencies in manufacturing for Inovio's CELLECTRA device, overstated regulatory and commercial prospects for INO-3107, and misleading public statements by the defendants [6]. Group 2: Regulatory Developments - On December 29, 2025, the FDA accepted Inovio's BLA for INO-3107 on a standard review timeline, indicating that the company did not provide sufficient information for accelerated approval [6]. - Following this announcement, Inovio's stock price dropped by $0.56, or 24.45%, closing at $1.73 per share [6]. Group 3: Legal Representation - Bragar Eagel & Squire, P.C. is representing the investors and encourages those affected to contact them for more information regarding their rights and potential claims [4][5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status set for April 7, 2026 [1] Group 1: Allegations Against Inovio Pharmaceuticals - The complaint alleges that Inovio and its executives made false and misleading statements regarding the manufacturing of the CELLECTRA device [1] - It is claimed that Inovio is unlikely to submit the Biologics License Application (BLA) for INO-3107 to the FDA by the second half of 2024 due to these deficiencies [1] - The company reportedly lacked sufficient information to justify the eligibility of INO-3107 for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [1] Group 2: Impact on Stock Price - Following the FDA's announcement that it accepted Inovio's BLA for INO-3107 on a standard review timeline, Inovio's stock price fell by $0.56 per share, or 24.45%, closing at $1.73 per share on December 29, 2025 [1] Group 3: Legal Proceedings and Investor Actions - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, overseeing the litigation on behalf of the class [1] - Any member of the putative class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [1]

Core Viewpoint - A class action has been filed against Inovio Pharmaceuticals, Inc. for allegedly misleading investors regarding the approval process for its CELLECTRA device and the INO-3107 Biologics License Application (BLA) [1] Group 1: Allegations and Issues - The complaint alleges that Inovio failed to disclose deficiencies in the manufacturing of its CELLECTRA device [1] - It is claimed that Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024 due to these manufacturing issues [1] - The company reportedly lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review [1] Group 2: Impact on Stock Price - Following a press release on August 8, 2024, revealing a delay in the INO-3107 BLA submission to mid-2025, Inovio's stock price fell by $0.27 per share, or 3.1%, closing at $8.44 per share on August 9, 2024 [1] - On December 29, 2025, after announcing that the FDA accepted the INO-3107 BLA on a standard review timeline, Inovio's stock price dropped by $0.56 per share, or 24.45%, closing at $1.73 per share [1] Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Inovio, with a deadline to submit papers to the court by April 7, 2026 [1] - The lead plaintiff will represent other class members in directing the litigation, but participation is not required for recovery [1]

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. for alleged securities fraud, with investors who purchased shares between October 10, 2023, and December 26, 2025, potentially entitled to compensation [1]. Group 1: Lawsuit Details - The lawsuit claims that Inovio made false and misleading statements regarding its CELLECTRA device manufacturing and the likelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 [1]. - It is alleged that Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [1]. - The lawsuit asserts that when the true details were revealed, investors suffered damages due to the misleading public statements made by the defendants [1]. Group 2: Legal Representation - The Rosen Law Firm, which is leading the class action, emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [1]. - The firm has a history of significant recoveries for investors, including over $438 million in 2019 alone, and has been recognized for its achievements in securities class action settlements [1]. - Investors interested in joining the class action can do so without upfront fees through a contingency fee arrangement [1].

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. for alleged violations of federal securities laws during the Class Period from October 10, 2023, to December 26, 2025, seeking to recover damages for affected investors [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Inovio and its officers made materially false and misleading statements regarding the company's business and operations throughout the Class Period [3]. - Specific allegations include that Inovio lacked sufficient information to justify the eligibility of the INO-3107 Biologics License Application (BLA) for FDA accelerated approval or priority review [3][8]. - Additional claims state that manufacturing for Inovio's CELLECTRA device was deficient, and thus, the submission of the INO-3107 BLA to the FDA by the second half of 2024 was unlikely [8]. Group 2: Investor Participation - Investors who purchased Inovio securities during the Class Period are encouraged to join the lawsuit, with a deadline to request lead plaintiff status by April 7, 2026 [2][3]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only recover costs if the lawsuit is successful [4]. Group 3: Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm specializing in securities fraud class actions and has recovered hundreds of millions of dollars for investors [5]. - The firm's mission focuses on restoring investor capital and ensuring corporate accountability to maintain market integrity [5].

Core Viewpoint - A class action lawsuit has been announced by Rosen Law Firm on behalf of purchasers of securities of Inovio Pharmaceuticals, Inc. for the period between October 10, 2023, and December 26, 2025, indicating potential legal challenges for the company [1]. Company Overview - Inovio Pharmaceuticals, Inc. is described as a biotechnology company focused on the discovery, development, and commercialization of DNA medicines aimed at treating and protecting individuals from diseases, including those associated with human papillomavirus (HPV) [1].